Rita S. Axelrod MD
Professor Medical Oncology Thomas Jefferson University; Director, Jefferson Oncology Group
Join to View Full Profile
925 Chestnut StSte 320APhiladelphia, PA 19107
Phone+1 215-955-8874
Fax+1 215-955-2340
Dr. Axelrod is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Main Line Health System/Lankenau Medical CenterFellowship, Hematology and Medical Oncology, 1975 - 1976
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1974 - 1975
Medical College of GeorgiaResidency, Internal Medicine, 1972 - 1973
Icahn School of Medicine at Mount Sinai/Morningside/WestInternship, Internal Medicine, 1970 - 1971
New York University School of MedicineClass of 1970
Certifications & Licensure
DE State Medical License 2017 - 2027
NJ State Medical License 1985 - 2027
PA State Medical License 1974 - 2026
NY State Medical License 1971 - 2014
GA State Medical License 1972 - 1995
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2012-2017
- CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR, Allscripts, 2012-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR (Complete), Allscripts, 2012-2017
Clinical Trials
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jul 19
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Start of enrollment: 2007 Dec 01
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Publications & Presentations
PubMed
- 2 citationsExtracellular Matrix-MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC.Pablo Llerena, Hani Samarah, Kathryn Nunes, Zhao Lin, Kelly Bridgham
Clinical Cancer Research. 2025-12-15 - 1 citationsNeoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm...Ralph G Zinner, Eric V Mastrolonardo, Jennifer M Johnson, Kathryn Nunes, Pablo Llerena
Clinical Cancer Research. 2025-12-12 - 3 citationsNeoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163.Nabil F Saba, Yael Flamand, Derrick T Lin, Christine H Chung, Mark W McDonald
Clinical Cancer Research. 2025-06-13
Press Mentions
Her Duty to HumanityOctober 29th, 2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
